Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-03
2006-10-03
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C530S330000, C530S331000, C530S345000
Reexamination Certificate
active
07115573
ABSTRACT:
The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
REFERENCES:
patent: 4277466 (1981-07-01), Trouet et al.
patent: 4296105 (1981-10-01), Baurain et al.
patent: 4376765 (1983-03-01), Trouet et al.
patent: 4388305 (1983-06-01), Trouet et al.
patent: 4639456 (1987-01-01), Trouet et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 4719312 (1988-01-01), Firestone
patent: 4870162 (1989-09-01), Trouet et al.
patent: 5024835 (1991-06-01), Rao et al.
patent: 5220001 (1993-06-01), Ok et al.
patent: 5393784 (1995-02-01), Richardson
patent: 5599686 (1997-02-01), DeFeo-Jones et al.
patent: 5618790 (1997-04-01), Kennedy et al.
patent: 5916921 (1999-06-01), Nishihira et al.
patent: 5962216 (1999-10-01), Trouet et al.
patent: 6143864 (2000-11-01), DeFeo-Jones et al.
patent: 6342480 (2002-01-01), Trouet et al.
patent: 6649587 (2003-11-01), Frydman et al.
patent: 6844318 (2005-01-01), Copeland et al.
patent: 2002/0142955 (2002-10-01), Dubois et al.
patent: 2003/0224971 (2003-12-01), Kumar et al.
patent: 869485 (1978-12-01), None
patent: 882541 (1980-07-01), None
patent: 0 041 935 (1981-12-01), None
patent: 0 044 090 (1982-01-01), None
patent: 0 126 685 (1984-11-01), None
patent: 0 208 615 (1987-01-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 93/02703 (1993-02-01), None
patent: WO 96/00503 (1996-01-01), None
patent: WO 96/05863 (1996-02-01), None
patent: WO 96/33198 (1996-10-01), None
patent: WO 00/33888 (2000-06-01), None
patent: WO 00/69472 (2000-11-01), None
patent: WO 01/28593 (2001-04-01), None
patent: WO 01/30804 (2001-05-01), None
Knight et al. Thimet oligopeptidase specificity . . . Biochemical Journal. 1995, vol. 308, pp. 145-150.
Nichifor et al. Polymeric prodrugs of 5-fluorouracil. Journal of Controlled Release. 1997, vol. 48, pp. 165-178.
Arribas et al. A Comparative Study of the Chymotrypsin-like Activity . . . The Journal Of Biological Chemistry. Oct. 5, 1993, vol. 268, No. 28, pp. 21165-21171.
M. Dayhoff, Atlas of Protein Sequence and Structure, vol. 5. National Biomedical Research Foundation, p. 96 (1972).
Kaneda et al. Antimetastatic effect of synthetic Glu-Ile-Leu-Asp-Val peptide derivatives containing D-amino acids. Anti-Cancer Drugs. 1997, vol. 8, pp. 702-707.
Baurain R, Masquelier M, Deprez-De Campeneere D, Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo. J Med Chem. Nov. 1980;23(11):1171-4.
Bricout, H., et al., “Synthetic and Kinetic Aspects of Nickel-Catalysed Amination of Allylic Alcohol Derivatives”, Tetrahedron, 1998, 54:1078-1084.
Casimir, J.R., et al., “First Application of the Dakin-west Reaction to Fmoc Chemistry: Synthesis of the ketomethylene tripeptide Fmoc-Na-ASP(tBu)-(R,S)Tyr(tBu)ψ(CO-CH2)Gly-OH”, 1995, Tetrahedron Letters, 1995, 36(27):4797-4800.
Chaires JB, Dattagupta N, Crothers DM. Self-association of daunomycin. Biochemistry. Aug. 17, 1982;21(17):3927-32.
Chakravarty PK, Carl PL, Weber MJ, Katzenellenbogen JA. Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard. J Med Chem. May 1983;26(5):633-8.
Eisenbrand, G., et al., “An Approach Towards More Selective Anticancer Agents”, Synthesis, 1996, pp. 1246-1258.
Genêt, J.P., et al., “A General and Simple Removal of the Allyloxycarbonyl Protecting Group by Palladium-Catalyzed Reactions Using Nitrogen and Sulfur Nucleophiles”, Synlett, Sep. 1993, No. 9:680-682.
Genêt, J.P., et al., “Practical Palladium-Meditated Deprotective Method of Allyloxycarbonyl in Aqueous Media”, Tetrahedron, 1994, 50(2):497-503.
Hayakawa, E., et al., “Viscosity Study on the Self-Association of Doxorubicin in Aqueous Solution”, Chem. Pharm. Bull., 1991, 39:1282-6.
Matzanke BF, Bill E, Butzlaff C, Trautwein AX, Winkler H, Hermes C, Nolting HF, Barbieri R, Russo U. Evidence for polynuclear aggregates of ferric daunomycin. A Mossbauer, EPR, X-ray absorption spectroscopy and magnetic susceptibility study. Eur J Biochem. Jul. 15, 1992;207(2):747-55.
Seitz, D.E., et al., “Synthesis and Chemical Properties of a Series of Doxonrubicin Enaminomalonyl-β-alanine Derivatives”, Tetrahedron Letters, 1995, 36(9):1413-1416.
Schmittberger et al., “Synthesis of the Palmitoylated and Prenylated C-terminal Lipopeptides of the Human R-and N-Ras Proteins” Biororg. Med. Chem., 1998, 7:749-762.
Balajthy Z, et al. Synthesis and functional evaluation of a peptide derivative of 1-beta-D-arabinofuranosylcytosine. J Med Chem. Sep. 4, 1992;35(18):3344-9.
Baurain, et al. Antitumor Activity of Daunorubicin linked to proteins: Lysosomal hydrolysis and antitumor activity of conjugates prepared with peptidic spacer arms. Current Chemotherapy and Immunotherapy, Proceeding of the 12thInternational Congress of Chemotherapy. 1982. pp. 1430-1432.
Baurain, et al. Targeting of Daunorubicin by Covalent & Reversible Linkage to carrier Proteins. Lysosomal Hydrolysis and Antitumoral Activity of Conjugates Prepared with Peptidic Spacer Arms. Drugs Exp. Clin. Res. 1983 9:303-311.
Carl PL, et al. Protease-activated “prodrugs” for cancer chemotherapy. Proc Natl Acad Sci U S A. Apr. 1980;77(4):2224-8.
Chakravarty PK, et al. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J Med Chem. May 1983;26(5):638-44.
DeFeo-Jones D, et al. A peptide-doxorubicin ‘prodrug’ activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med. Nov. 2000;6(11):1248-52.
De Marre, et al. Evaluation of the hydrolytic and enzymatic stability of macromolecular Mitimycin C derivatives. Journal of Controlled Release. 1994 31:89-97.
Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem. Jul.-Aug. 2001;36(7-8):577-95.
Harnois-Pontoni M, et al. Hydrosoluble fluorogenic substrates for plasmin. Anal Biochem. Mar. 2, 1991;193(2):248-55.
Israel M, et al. Adriamycin analogues. Preparation and biological evaluation of some N-(trifluoroacetyl)-14-O-[(N-acetylamino)acyl]adriamycin derivatives. J Med Chem. Jul. 1986;29(7):1273-6.
Kandukuri, S.P., et al. Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias. J Med Chem. Aug. 1985;28(8):1079-88.
Kennett CN, et al. Comparative histochemical, biochemical and immunocytochemical studies of cathepsin B in human gingiva. J Periodontal Res. May 1994;29(3):203-13.
Masquelier M, et al. Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J Med Chem. Nov. 1980;23(11):1166-70.
Masquelier, et al. Antitumor Activity of Daunorubicin Linked to Proteins: Biological and Antitumor Properties of Peptidic Derivatives of Daunorubicin Used as Intermediates. Current Chemotherapy and Immunotherapy, Proceedings of the 12thInternational Congress of Chemotherapy. 1982, pp. 1428-1430.
Mayer R, et al. Peptide derivatives specific for a Plasmodium falciparum proteinase inhibit the human erythrocyte invasion by merozoites. J Med Chem. Oct. 1991;34(10):3029-35.
Moss, Judi. Peptide Prodrugs Designed to Limit Metabolism. Washington DC. Am. Chem. Soc., 1995. Chapters 18, pp. 423-445.
Nestor, John J. Improved Duration of Action of Peptide Drugs. Washington DC. Am. Chem. Soc., 1995. p. 449-471.
Pan C, et al. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of nove
Gangwar Sanjeev
Lobl Thomas J.
Nieder Matthew H.
Pickford Lesley B.
Yarranton Geoffrey T.
Lahive & Cockfield LLP
Medarex Inc.
Remillard, Esq. Jane R.
Russel Jeffrey Edwin
Soroos, Esq. Cynthia M.
LandOfFree
Prodrug compounds with an isoleucine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrug compounds with an isoleucine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrug compounds with an isoleucine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3702312